NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced financial results for the fourth quarter and full-year ended December 31, 2006.
